Signature Equity Partners’s Genmab GMAB Stock Holding History

Signature Equity Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.05K	Buy	111 +42	+61%	+$1.12K	﹤0.01%	1095
2026 Q1	$1.85K	Hold	69	–	–	﹤0.01%	1135
2025 Q4	$2.13K	Buy	+69	New	+$2.15K	﹤0.01%	1196

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Signature Equity Partners's GMAB Position: Q2 2026 in Review

Signature Equity Partners increased its Genmab (GMAB) stake by 61% in Q2 2026, buying an estimated $1.12K and bringing the position to 111 shares worth $3.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Signature Equity Partners first reported a position in GMAB in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Signature Equity Partners held 111 shares of Genmab worth $3.05K as of Q2 2026.
Signature Equity Partners bought 42 Genmab shares in Q2 2026, an estimated $1.12K.
Genmab made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1095 holding.
Signature Equity Partners first reported a position in Genmab in Q4 2025 and has held it in 3 quarters since.
289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.